Pyrimidine-cycloalkyl compounds, their preparation methods and their pharmaceutical applications

By designing pyrimidine-cycloalkyl compounds, the problem of the lack of KRAS G12D inhibitors in the existing technology has been solved, and effective inhibition of KRAS G12D mutations has been achieved, which has the potential to treat a variety of cancers.

CN115385937BActive Publication Date: 2026-11-17JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202210570041.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-12-09
Filing Date
2022-05-24
Publication Date
2026-11-17
Estimated Expiration
2042-05-24

AI Technical Summary

Technical Problem

The lack of effective KRAS G12D inhibitors in current technologies leaves most KRAS-mutant cancer patients without treatment options, especially since KRAS G12D mutations are widely and highly expressed in various tumors, and existing patents have failed to provide effective means of inhibition.

Method used

A series of pyrimidine cycloalkyl compounds and their pharmaceutically usable salts have been developed. Through the design of specific structures, the aryl or heteroaryl combinations of ring A and ring B are preferred, and different substituents are selected to form compounds with potential pharmaceutical value for the preparation of drugs that inhibit KRAS G12D.

Benefits of technology

It provides an effective means of inhibiting KRAS G12D mutations, which has potential clinical application value and can be used to treat a variety of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115385937B_ABST
    Figure CN115385937B_ABST
Patent Text Reader

Abstract

This disclosure relates to pyrimidine-cycloalkyl compounds, their preparation methods, and their pharmaceutical applications. Specifically, this disclosure relates to a pyrimidine-cycloalkyl compound of general formula (I), its preparation method, pharmaceutical compositions containing such compounds, and its use as a therapeutic agent, particularly its use in the preparation of medicaments for inhibiting KRAS G12D. The groups in general formula (I) are as defined in the specification.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure pertains to the pharmaceutical field and relates to a pyrimidine-cycloalkyl compound, its preparation method, and its pharmaceutical application. In particular, this disclosure relates to pyrimidine-cycloalkyl compounds of general formula (I), their preparation methods, pharmaceutical compositions containing such compounds, and their use in the preparation of medicaments for inhibiting KRAS G12D. Background Technology

[0002] RAS (Rapid Acid Spectroscopy) genes are among the most frequently mutated oncogenes in tumors, with approximately 30% of human malignancies associated with RAS gene mutations. The RAS family includes KRAS, NRAS, and HRAS, with KRAS mutations being the most common, accounting for about 85%. KRAS mutations are common in solid tumors, showing high frequency in the three leading causes of cancer death in humans—lung cancer (17%), colorectal cancer (33%), and pancreatic cancer (61%). In KRAS gene mutations, 97% involve mutations at amino acid residues 12 or 13, with G12D being a significant mutation. Data analysis of European and American populations shows that G12D mutations account for 36%, 12%, and 4% of patients with pancreatic cancer, colorectal cancer, and non-small cell lung cancer, respectively.

[0003] Once activated, KRAS regulates various functions of cell proliferation, survival, migration, and metabolism through numerous downstream signaling pathways, including RAF-MEK-ERK, PI3K-AKT-mTOR, and TIAM1-RAc. Mutations in the KRAS gene result in a persistently activated protein, leading to continued activation of downstream signaling pathways and promoting tumorigenesis.

[0004] Because the KRAS protein lacks traditional small-molecule binding sites and has an extremely high affinity for guanosine monophosphate (GMP), making it very difficult to inhibit, it has long been considered an untreatable drug target. However, given the importance and prevalence of abnormal KRAS activation in cancer progression, KRAS remains a highly anticipated target in drug development. Currently, apart from KRAS G12C inhibitors, there are still no effective KRAS inhibitors against other mutations, leaving most patients with KRAS mutations without a cure. G12D, as a mutant widely and highly expressed in various tumors, presents significant clinical implications for the development of inhibitors.

[0005] Currently published related patent applications include WO2021041671A1, WO2020146613A1, WO2017172979A1, WO2020238791A1 and WO2019155399A1, etc. Summary of the Invention

[0006] The purpose of this disclosure is to provide a compound of general formula (I) or a pharmaceutically acceptable salt thereof:

[0007]

[0008] in:

[0009] G 2 For NR d ;

[0010] Ring A is aryl or heteroaryl;

[0011] Ring B is selected from cycloalkyl, heterocyclic, aryl, and heteroaryl groups;

[0012] L is selected from single bond, O, and NR. e ;

[0013] R 1 They may be the same or different, and each is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, and -(CH2). u -NR f R g hydroxyl and hydroxyalkyl;

[0014] R 2 R 2c R 2a R 2b R 4a and R 4b They may be the same or different, and each is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, and -(CH2). v -NR h R i hydroxyl, hydroxyalkyl and cycloalkyl; or

[0015] R 2 R 2c With the attached carbon atom, or R 2a R 2b With the attached carbon atom, or R 4a R 4b Together with the attached carbon atom, it forms a cycloalkyl or heterocyclic group;

[0016] R 3 and R 6 They may be the same or different, and each is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, and -(CH2). w -NR j R k Nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl;

[0017] R 5 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, cyano groups, hydroxyl groups, and hydroxyalkyl groups;

[0018] R d R e R f R g R h R i R j and R k They may be the same or different, and each is independently selected from hydrogen atoms, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;

[0019] u, v, and w may be the same or different, and each is independently selected from 0, 1, 2, and 3;

[0020] m is 0, 1, or 2;

[0021] n is 0 or 1;

[0022] r is 0, 1, or 2;

[0023] p is 0, 1, 2, 3, 4 or 5;

[0024] q is 0, 1, 2, 3, 4, or 5; and

[0025] t can be 0, 1, 2, 3, 4 or 5.

[0026] Another aspect of this disclosure relates to a compound of general formula (I-1) or a pharmaceutically acceptable salt thereof:

[0027]

[0028] in

[0029] q can be 0, 1, 2, 3, or 4;

[0030] G 2 Ring A, Ring B, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, r and t are as defined in general formula (I).

[0031] In some preferred embodiments of this disclosure, the compound represented by general formula (I) or (I-1) or its pharmaceutically usable salt, wherein ring A is a 6- to 10-membered aryl or a 5- to 10-membered heteroaryl; preferably, ring A is phenyl or naphthyl; more preferably naphthyl.

[0032] In some preferred embodiments of this disclosure, the compound represented by general formula (I) or (I-1) or a pharmaceutically acceptable salt thereof, wherein ring B is a 7- to 10-membered fused heterocyclic group, R 6 It can replace any position of the ring B; preferably, the ring B is R 6 It can be replaced at any position in ring B; more preferably, for R 6 As defined in general formula (I); more preferably, for R 6 Halogen; most preferably, for R 6 It is a halogen (preferably F).

[0033] In some preferred embodiments of this disclosure, the compound represented by general formula (I) or (I-1) or its pharmaceutically acceptable salt, wherein ring A is phenyl or naphthyl; and / or ring B is R 6 It can be replaced at any position in ring B.

[0034] Another aspect of this disclosure relates to a compound of general formula (II) or a pharmaceutically acceptable salt thereof:

[0035]

[0036] in

[0037] G 2 Ring A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in general formula (I).

[0038] Another aspect of this disclosure relates to a compound of general formula (II-1) or a pharmaceutically acceptable salt thereof:

[0039]

[0040] in

[0041] q can be 0, 1, 2, 3, or 4;

[0042] G 2 Ring A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, r and t are as defined in general formula (I).

[0043] In some preferred embodiments of this disclosure, the compound represented by general formula (I) or (II) or a pharmaceutically acceptable salt thereof, wherein for R 3 The definition is as defined in general formula (I); preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl, hydroxyl, C 1-6 Hydroxyalkyl and 3- to 8-membered cycloalkyl; more preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 Alkyne, hydroxyl, and cyclopropyl; more preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, ethyl groups, hydroxyl groups, and cyclopropyl groups; most preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, ethyl groups, and hydroxyl groups.

[0044] In some embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein ring A is phenyl, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl, hydroxyl, C 1-6 Hydroxyalkyl and 3- to 8-membered cycloalkyl; preferably, ring A is phenyl, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, hydroxyl groups, and 3 to 8-membered cycloalkyl groups; more preferably, ring A is phenyl, and R is... 3They may be the same or different, and each is independently selected from hydrogen atoms, halogens, hydroxyl groups, and cyclopropyl groups.

[0045] In some preferred embodiments of this disclosure, the compound represented by general formula (II) or (II-1) or its pharmaceutically usable salt, wherein ring A is a 6- to 10-membered aryl or a 5- to 10-membered heteroaryl; preferably, ring A is phenyl or naphthyl; more preferably naphthyl.

[0046] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R d It is a hydrogen atom or a carbon atom. 1-6 Alkyl; preferably, R d It is a hydrogen atom.

[0047] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically acceptable salt, wherein n is 0.

[0048] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically usable salt is wherein m is 1 or 2; preferably, m is 1.

[0049] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 2 and R 2c They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl, or R 2 R 2c Together with the attached carbon atom, it forms a 3- to 8-membered cycloalkyl group or a 3- to 8-membered heterocyclic group; preferably, R 2 and R 2c They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl; more preferably, R 2 and R 2c All are hydrogen atoms.

[0050] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 2a and R 2b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl, or R 2a R 2bTogether with the attached carbon atom, it forms a 3- to 8-membered cycloalkyl group or a 3- to 8-membered heterocyclic group; preferably, R 2a and R 2b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl; more preferably, R 2a and R 2b They may be the same or different, and each is independently a hydrogen atom or a methyl group; most preferably, R 2a For hydrogen atoms, R 2b It is a methyl group.

[0051] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 2a Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; preferably, R 2a It is a hydrogen atom.

[0052] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 2b Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; preferably, R 2b C 1-6 Alkyl; more preferably methyl.

[0053] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 4a and R 4b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl, or R 4a R 4b Together with the attached carbon atom, it forms a 3- to 8-membered cycloalkyl group or a 3- to 8-membered heterocyclic group; preferably, R 4a and R 4b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 alkyl.

[0054] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 2a and R 2b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6Halogenated alkyl, or R 2a R 2b Together with the attached carbon atom, it forms a 3- to 8-membered cycloalkyl group or a 3- to 8-membered heterocyclic group; and / or R 4a and R 4b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl, or R 4a R 4b Together with the attached carbon atom, it forms a 3- to 8-membered cycloalkyl group or a 3- to 8-membered heterocyclic group; preferably, R 2a and R 2b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl; and / or R 4a and R 4b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 alkyl.

[0055] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically acceptable salt, wherein G 2 It is NH.

[0056] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically acceptable salt thereof, wherein L is O.

[0057] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R e It is a hydrogen atom or a carbon atom. 1-6 Alkyl; preferably, R e It is a hydrogen atom.

[0058] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 1 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 1-6 Halogenated alkyl, cyano, amino, -(CH2) u -NR f R g hydroxyl and C 1-6 Hydroxyalkyl, R f and R g They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl group, u is 0 or 1; preferably, R 1They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl; more preferably, R 1 It is a hydrogen atom.

[0059] In some preferred embodiments of this disclosure, the compound represented by general formula (I) or (II) or a pharmaceutically acceptable salt thereof, wherein R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, cyano, amino, -(CH2) w -NR j R k hydroxyl and C 1-6 Hydroxyalkyl, R j and R k They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl group, w is 0 or 1; preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 alkynyl group, C 1-6 Halogenated alkyl, hydroxyl, C 1-6 Hydroxyalkyl and 3- to 8-membered cycloalkyl; more preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 Alkyne, hydroxyl, and cyclopropyl; most preferably, R 3 They may be the same or different, and each is independently selected from hydrogen, halogen, ethyl, hydroxyl and cyclopropyl.

[0060] In some preferred embodiments of this disclosure, the compound represented by general formula (I-1) or (II-1) or its pharmaceutically acceptable salt, wherein R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, cyano, amino, -(CH2) w -NR j R k and C 1-6 Hydroxyalkyl, R j and Rk They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl group, w is 0 or 1; preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl and 3- to 8-membered cycloalkyl; more preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 Alkyne and cyclopropyl; most preferably, R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, ethyl groups, and cyclopropyl groups.

[0061] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 5 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxyl and C 1-6 Hydroxyalkyl; preferably, R 5 Whether the atoms are the same or different, and each is independently selected from hydrogen atoms, C atoms 1-6 Alkyl, hydroxyl and C 1-6 Hydroxyalkyl; more preferably, R 5 It is a hydrogen atom.

[0062] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or a pharmaceutically acceptable salt thereof, wherein R 6 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, cyano, amino, -(CH2) w -NR j R k hydroxyl and C 1-6 Hydroxyalkyl, R j and R k They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl group, w is 0 or 1; preferably, R 6 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl group; more preferably halogen; most preferably F.

[0063] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically usable salt is used, wherein r is 0 or 1, preferably 1.

[0064] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically usable salt, wherein p is 0 or 1, preferably 1.

[0065] In some preferred embodiments of this disclosure, the compound represented by general formula (I) or (II) or its pharmaceutically usable salt, wherein q is 1, 2 or 3, preferably 2.

[0066] In some preferred embodiments of this disclosure, the compound represented by general formula (I-1) or (II-1) or its pharmaceutically acceptable salt thereof, wherein q is 0, 1 or 2.

[0067] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically usable salt, wherein t is 1 or 2, preferably 1.

[0068] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically acceptable salt thereof, wherein u is 0 or 1.

[0069] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically acceptable salt thereof, wherein v is 0 or 1.

[0070] In some preferred embodiments of this disclosure, the compound represented by general formula (I), (I-1), (II) or (II-1) or its pharmaceutically acceptable salt, wherein w is 0 or 1.

[0071] In some preferred embodiments of this disclosure, the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, wherein G 2 For NH; ring A is a 6- to 10-membered aryl or a 5- to 10-membered heteroaryl; L is O; p is 1; R 1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; R 2 R 2c R 2a R 2b R 4a and R 4b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6Alkyl and C 1-6 Halogenated alkyl; or R 2 R 2c With the attached carbon atom, or R 2a R 2b With the attached carbon atom, or R 4a R 4b Together with the attached carbon atom, it forms a 3- to 8-membered cycloalkyl group or a 3- to 8-membered heterocyclic group; q is 1 or 2; R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 Alkyne, hydroxyl, and cyclopropyl; r is 0 or 1; R 5 Selected from hydrogen atoms, C 1-6 Alkyl, hydroxyl and C 1-6 Hydroxyalkyl; t is 1; R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; m is 1; and n is 0.

[0072] In some embodiments of this disclosure, the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, wherein G 2 For NH; ring A is phenyl or naphthyl; L is O; p is 1; R 1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; R 2 R 2c R 2a R 2b R 4a and R 4b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Haloalkyl; q is 1 or 2; R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 Alkyne, hydroxyl, and cyclopropyl; r is 0 or 1; R 5 Selected from hydrogen atoms, C 1-6 Alkyl, hydroxyl and C 1-6 Hydroxyalkyl; t is 1; R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; m is 1; and n is 0.

[0073] In some embodiments of this disclosure, the compound represented by general formula (II-1) or a pharmaceutically acceptable salt thereof, wherein G 2 For NH; ring A is phenyl or naphthyl; L is O; p is 1; R1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; R 2 R 2c R 2a R 2b R 4a and R 4b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Haloalkyl; q is 0, 1 or 2; R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl, C 2-6 Alkyne and cyclopropyl; r is 0 or 1; R 5 Selected from hydrogen atoms, C 1-6 Alkyl, hydroxyl and C 1-6 Hydroxyalkyl; t is 1; R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; m is 1; and n is 0.

[0074] Table A lists typical compounds disclosed herein, including but not limited to:

[0075]

[0076]

[0077]

[0078]

[0079]

[0080]

[0081]

[0082]

[0083]

[0084]

[0085]

[0086]

[0087]

[0088]

[0089] Another aspect of this disclosure relates to compounds of general formula (IA) or salts thereof.

[0090]

[0091] in,

[0092] R is an amino protecting group; preferably Boc;

[0093] Ring A, Ring B, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in general formula (I).

[0094] Another aspect of this disclosure relates to compounds of general formula (I-1A) or salts thereof.

[0095]

[0096] in,

[0097] q can be 0, 1, 2, 3, or 4;

[0098] R 0 The protecting group is a hydrogen atom or a hydroxyl group; the hydroxyl protecting group is preferably a MOM.

[0099] R is an amino protecting group; preferably Boc;

[0100] Ring A, Ring B, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, r and t are defined as in general formula (I-1).

[0101] Another aspect of this disclosure relates to compounds of general formula (IIA) or salts thereof.

[0102]

[0103] in,

[0104] R is an amino protecting group; preferably Boc;

[0105] Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in general formula (II).

[0106] Another aspect of this disclosure relates to compounds of general formula (II-1A) or salts thereof.

[0107]

[0108] in,

[0109] q can be 0, 1, 2, 3, or 4;

[0110] R 0 The protecting group is a hydrogen atom or a hydroxyl group; the hydroxyl protecting group is preferably a MOM.

[0111] R is an amino protecting group; preferably Boc;

[0112] Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, r and t are defined as in general formula (II-1).

[0113] In some preferred embodiments of this disclosure, the compound represented by general formula (I-1A) or (II-1A) or its pharmaceutically acceptable salt, wherein R 0 It can be MOM or Bn.

[0114] Typical intermediate compounds disclosed herein include, but are not limited to:

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122]

[0123]

[0124]

[0125]

[0126]

[0127]

[0128]

[0129] Another aspect of this disclosure relates to a method for preparing a compound of general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:

[0130]

[0131] A compound of general formula (IA) or a salt thereof undergoes a deprotection reaction to yield a compound of general formula (I) or a pharmaceutically usable salt thereof; optionally, when R 3 and / or R 6 When the group contains a protecting group, the removal of R is also included before, during, or after the deprotection reaction. 3 and / or R 6 The step of adding a protecting group to the group; preferably, the protecting group is a hydroxyl protecting group (MOM);

[0132] in,

[0133] R is an amino protecting group; preferably Boc;

[0134] G 2 For NH;

[0135] Ring A, Ring B, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in general formula (I).

[0136] Another aspect of this disclosure relates to a method for preparing a compound of general formula (I-1) or a pharmaceutically acceptable salt thereof, the method comprising:

[0137]

[0138] R 0 The protecting group is a hydrogen atom or a hydroxyl group; the hydroxyl protecting group is preferably a MOM.

[0139] When R 0 When the hydrogen atom is present, the compound of general formula (I-1A) or its salt is deamino protecting group R to obtain the compound of general formula (I-1) or its pharmaceutically usable salt.

[0140] When R 0 When the protecting group is a hydroxyl group, compounds of general formula (I-1A) or their salts lose the hydroxyl protecting group R. 0 With an amino protecting group R, a compound of general formula (I-1) or its pharmaceutically usable salt is obtained;

[0141] in,

[0142] R is an amino protecting group; preferably Boc;

[0143] G 2 For NH;

[0144] Ring A, Ring B, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 , m, n, p, q, r and t are as defined in general formula (I-1).

[0145] Another aspect of this disclosure relates to a method for preparing a compound of general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:

[0146]

[0147] A compound of general formula (IIA) or a salt thereof undergoes a deprotection reaction to yield a compound of general formula (II) or a pharmaceutically usable salt thereof; optionally, when R 3 and / or R 6 When the group contains a protecting group, the removal of R is also included before, during, or after the deprotection reaction. 3 and / or R 6The step of adding a protecting group to the group; preferably, the protecting group is a hydroxyl protecting group (MOM);

[0148] Where R is an amino protecting group; preferably Boc;

[0149] G 2 For NH;

[0150] Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in general formula (II).

[0151] Another aspect of this disclosure relates to a method for preparing a compound of general formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising:

[0152]

[0153] R 0 The protecting group is a hydrogen atom or a hydroxyl group; the hydroxyl protecting group is preferably a MOM.

[0154] When R 0 When the hydrogen atom is present, the compound of general formula (II-1A) or its salt is deamino protecting group R to obtain the compound of general formula (II-1) or its pharmaceutically usable salt.

[0155] When R 0 When the protecting group is hydroxyl, compounds of general formula (II-1A) or their salts lose the hydroxyl protecting group R. 0 With an amino protecting group R, a compound of general formula (II-1) or its pharmaceutically usable salt is obtained;

[0156] in,

[0157] R is an amino protecting group; preferably Boc;

[0158] G 2 For NH;

[0159] Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6m, n, p, q, r and t are as defined in general formula (II-1).

[0160] Another aspect of this disclosure relates to a pharmaceutical composition comprising a compound of formula (I), (I-1), (II), (II-1) or shown in Table A of this disclosure or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0161] This disclosure further relates to the use of compounds of general formula (I), (I-1), (II), (II-1) or shown in Table A, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising thereof, in the preparation of a medicament for inhibiting KRAS G12D.

[0162] This disclosure further relates to the use of compounds of general formulas (I), (I-1), (II), (II-1) or Table A, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising thereof, in the preparation of medicaments for treating and / or preventing diseases or conditions, wherein the disease or condition is cancer; the disease or condition is preferably selected from brain cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, pharyngeal cancer, oral cancer, salivary gland cancer, esophageal cancer, gastric cancer, lung cancer, liver cancer, kidney cancer, pleural cancer, peritoneal cancer, pancreatic cancer, and gallbladder cancer. Cancer, bile duct cancer, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, urothelial carcinoma, urethral cancer, bladder cancer, anal cancer, joint cancer, breast cancer, vaginal cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, hemangioma, leukemia, lymphoma, myeloma, skin cancer, melanoma, lipoma, bone cancer, soft tissue sarcoma, neurofibroma, glioma, neuroblastoma, and glioblastoma; further preferably selected from pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

[0163] This disclosure further relates to a method of inhibiting KRAS G12D, comprising administering to a patient a therapeutically effective amount of a compound of general formula (I), (I-1), (II), (II-1) or shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.

[0164] This disclosure further relates to a method of treating and / or preventing a disease or condition, comprising administering to a desired patient a therapeutically effective amount of a compound of general formula (I), (I-1), (II), (II-1) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, wherein the disease or condition is cancer; preferably selected from brain cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, pharyngeal cancer, oral cancer, salivary gland cancer, esophageal cancer, gastric cancer, lung cancer, liver cancer, kidney cancer, pleural cancer, peritoneal cancer, pancreatic cancer, etc. Adenocarcinoma, gallbladder cancer, bile duct cancer, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, urothelial carcinoma, urethral cancer, bladder cancer, anal cancer, joint cancer, breast cancer, vaginal cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, hemangioma, leukemia, lymphoma, myeloma, skin cancer, melanoma, lipoma, bone cancer, soft tissue sarcoma, neurofibroma, glioma, neuroblastoma, and glioblastoma; further preferably selected from pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

[0165] This disclosure further relates to a compound of general formula (I), (I-1), (II), (II-1) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof, which is used as a medicine.

[0166] This disclosure further relates to a compound of general formula (I), (I-1), (II), (II-1) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the thereof, which is used as a medicament for inhibiting KRAS G12D.

[0167] This disclosure further relates to a compound of general formula (I), (I-1), (II), (II-1) or Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the thereof, used as a medicine for treating and / or preventing a disease or condition, wherein the disease or condition is cancer; the disease or condition is preferably selected from brain cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, laryngeal cancer, oral cancer, salivary gland cancer, esophageal cancer, gastric cancer, lung cancer, liver cancer, kidney cancer, pleural cancer, peritoneal cancer, pancreatic cancer, and gallbladder cancer. Cholangiocarcinoma, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, urothelial carcinoma, urethral cancer, bladder cancer, anal cancer, joint cancer, breast cancer, vaginal cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, hemangioma, leukemia, lymphoma, myeloma, skin cancer, melanoma, lipoma, bone cancer, soft tissue sarcoma, neurofibroma, glioma, neuroblastoma, and glioblastoma; further preferably selected from pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

[0168] The diseases or conditions described in this disclosure are those that are treated and / or prevented by inhibiting KRAS G12D.

[0169] The colorectal cancer described in this disclosure is preferably colon cancer or rectal cancer.

[0170] Preferably, the brain cancer described in this disclosure is selected from glioblastoma multiforme or neuroblastoma; the soft tissue cancer is selected from fibrosarcoma, gastrointestinal sarcoma, rhabdomyosarcoma, leiomyosarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, malignant fibrous histiocytoma, round cell sarcoma, and synovial sarcoma; the lymphoma is selected from Hodgkin's disease and non-Hodgkin's lymphoma (e.g., mantle cell lymphoma, diffuse large B-cell lymphoma, follicular center lymphoma, marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, and peripheral T-cell lymphoma); the liver cancer is preferably hepatocellular carcinoma; and the lung cancer (also known as bronchogenic carcinoma) is selected from... Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and squamous cell carcinoma; renal cell carcinoma is selected from renal cell carcinoma, clear cell carcinoma, and renal eosinophilic cell carcinoma; leukemia is selected from chronic lymphocytic leukemia (CLL), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), T-cell acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML); skin cancer is selected from malignant melanoma, squamous cell carcinoma, basal cell carcinoma, and angiosarcoma; myeloma is preferably multiple myeloma.

[0171] The active compounds can be formulated into forms suitable for administration via any appropriate route, using one or more pharmaceutically acceptable carriers through conventional methods. Therefore, the active compounds of this disclosure can be formulated into various dosage forms for oral administration, injection (e.g., intravenous, intramuscular, or subcutaneous), inhalation, or insufflation. The compounds of this disclosure can also be formulated into dosage forms such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injections, dispersible powders or granules, suppositories, lozenges, or syrups.

[0172] As a general guideline, the active compound is preferably expressed in a unit dose manner, or in a manner that allows the patient to self-administer a single dose. The unit dose of the disclosed compound or composition may be expressed as a tablet, capsule, sachet, bottled liquid, powder, granule, lozenge, suppository, regenerated powder, or liquid formulation. Suitable unit doses may range from 0.1 to 1000 mg.

[0173] In addition to the active compound, the pharmaceutical compositions disclosed herein may contain one or more excipients selected from the following: fillers (diluents), binders, wetting agents, disintegrants, or excipients. Depending on the method of administration, the composition may contain 0.1 to 99% by weight of the active compound.

[0174] Tablets contain an active ingredient and non-toxic, pharmaceutically acceptable excipients suitable for tablet preparation, used for mixing. These excipients may be inert excipients, granulating agents, disintegrants, binders, and lubricants. These tablets may be uncoated or coated using known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thus providing sustained release over a longer period.

[0175] Oral formulations can also be provided using soft gelatin capsules in which the active ingredient is mixed with an inert solid diluent or in which the active ingredient is mixed with a water-soluble carrier or an oil solvent.

[0176] Aqueous suspensions contain active substances and excipients suitable for preparing aqueous suspensions, used for mixing. These excipients are suspending agents, dispersing agents, or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweeteners.

[0177] Oil suspensions are prepared by suspending the active ingredient in vegetable or mineral oil. Oil suspensions may contain thickeners. Sweeteners and flavoring agents mentioned above may be added to provide palatable formulations. These compositions may be preserved by adding antioxidants.

[0178] The pharmaceutical compositions disclosed herein may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil, a mineral oil, or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsion may also contain sweeteners, flavoring agents, preservatives, and antioxidants. Such formulations may also contain modifiers, preservatives, colorants, and antioxidants.

[0179] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous solutions. Acceptable solvents or media that can be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase, which can be injected into the patient's bloodstream via local large-volume injection. Alternatively, the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compounds disclosed herein. To maintain such a constant concentration, a continuous intravenous delivery device can be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous infusion pump.

[0180] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous or oil suspensions for intramuscular and subcutaneous administration. These suspensions may be formulated using suitable dispersants or wetting agents and suspending agents as described above, according to known techniques. The sterile injectable formulations may also be sterile injectable solutions or suspensions prepared in parenteral acceptable non-toxic diluents or solvents. Furthermore, sterile fixative oils can be conveniently used as solvents or suspension media. Any blended fixative oil may be used for this purpose. Additionally, fatty acids may also be used to prepare injectable formulations.

[0181] The disclosed compounds can be administered in suppository form for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable, non-irritating excipient that is solid at normal temperatures but liquid in the rectum, and thus dissolves in the rectum to release the drug.

[0182] The compounds disclosed herein can be administered by adding water to prepare water-soluble dispersible powders and granules. These pharmaceutical compositions can be prepared by mixing the active ingredient with a dispersant or wetting agent, a suspending agent, or one or more preservatives.

[0183] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to: the activity of the specific compound used, the severity of the disease, the patient's age, the patient's weight, the patient's health status, the patient's behavior, the patient's diet, the timing of administration, the route of administration, the rate of excretion, and the combination of drugs; in addition, the optimal treatment mode, such as the treatment regimen, the daily dosage of the compound, or the type of pharmaceutically acceptable salt, can be validated based on conventional treatment protocols.

[0184] Terminology Explanation

[0185] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0186] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably an alkyl group having 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C12). 1-12 Alkyl groups, more preferably alkyl groups having 1 to 6 carbon atoms (i.e., C1646-C ... 1-6Alkyl groups). Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their various branched isomers, etc. Alkyl groups can be substituted or unsubstituted, and when substituted, they can be substituted at any usable connection point. The substituents are preferably independently selected independently from one or more of the following: D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0187] The term "alkylene" refers to a saturated straight-chain or branched aliphatic hydrocarbon group, which is a residue derived from a parent alkane by removing two hydrogen atoms from the same carbon atom or two different carbon atoms. It is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably having 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C64). 1-12 Alkylenes, more preferably alkylenes having 1 to 6 carbon atoms (i.e., C16-164 ... 1-6Alkylenes. Non-limiting examples of alkylenes include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), etc. Alkylenes can be substituted or unsubstituted, and when substituted, they can be substituted at any usable linking point. Substituents are preferably selected from one or more of alkenyl, alkynyl, alkoxy, haloalkoxy, cycloalkyloxy, heterocyclic alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, and oxo.

[0188] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in a molecule, wherein the definition of alkyl is as described above. Preferably, alkenyl groups (i.e., C14-C14) have 2 to 12 carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12). 2-12 Alkenyl), more preferably alkenyl containing 2 to 6 carbon atoms (i.e., C14-C ... 2-6 Alkenyl). Non-limiting examples include vinyl, propenyl, isopropenyl, butenyl, etc. Alkenyl groups can be substituted or unsubstituted, and when substituted, the substituents are preferably selected from one or more of alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0189] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in a molecule, wherein the definition of alkyl is as described above. Preferably, the alkynyl group (i.e., C14) has 2 to 12 carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12). 2-12 Alkyne group), more preferably an alkyne group containing 2 to 6 carbon atoms (i.e., C12-C64 ... 2-6 (Alynyl). Non-limiting examples include: ethynyl, propynyl, butynyl, pentyynyl, hexynyl, etc. The alkynyl group can be substituted or unsubstituted, and when substituted, the substituent is preferably selected from one or more of alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0190] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring comprises 3 to 20 carbon atoms (i.e., 3 to 20-membered cycloalkyl), preferably 3 to 14 carbon atoms (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14) (i.e., 3 to 14-membered cycloalkyl), more preferably 3 to 8 carbon atoms (e.g., 3, 4, 5, 6, 7, and 8) (i.e., 3 to 8-membered cycloalkyl), and more preferably 3 to 6 carbon atoms (i.e., 3 to 6-membered cycloalkyl). Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc.; polycyclic cycloalkyl includes spirocycloalkyl, fused cycloalkyl, and bridged cycloalkyl.

[0191] The term "spirocycloalkyl" refers to a 5- to 20-membered polycyclic group (i.e., a 5- to 20-membered spirocycloalkyl group) that shares a single carbon atom (called a spiro atom) between the rings, and may contain one or more double bonds. Preferably, it is 6- to 14-membered (i.e., 6- to 14-membered spirocycloalkyl), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered spirocycloalkyl). Spirocycloalkyl groups are classified into monospirocycloalkyl and polyspirocycloalkyl (such as bispirocycloalkyl) based on the number of shared spiro atoms between the rings, with monospirocycloalkyl and bispirocycloalkyl being preferred. More preferably, it is a monospirocycloalkyl group consisting of 3 / 4, 3 / 5, 3 / 6, 4 / 4, 4 / 5, 4 / 6, 5 / 3, 5 / 4, 5 / 5, 5 / 6, 5 / 7, 6 / 3, 6 / 4, 6 / 5, 6 / 6, 6 / 7, 7 / 5, or 7 / 6. Non-limiting examples of spirocycloalkyl groups include:

[0192]

[0193] The term "fused cycloalkyl" refers to a 5- to 20-membered polycyclic aromatic hydrocarbon group (PAH) in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds. Preferably, it is a 6- to 14-membered PAH, more preferably a 7- to 10-membered PAH (e.g., 7, 8, 9 or 10-membered PAH) (i.e., 7- to 10-membered PAH). Based on the number of rings, fused alkyl groups can be classified into bicyclic and polycyclic (e.g., tricyclic, tetracyclic, etc.) cyclic alkyl groups, preferably bicyclic or tricyclic, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered bicyclic fused alkyl groups. Non-limiting examples of fused alkyl groups include:

[0194]

[0195] The term "bridged cycloalkyl" refers to a 5- to 20-membered (i.e., 5- to 20-membered bridged cycloalkyl) all-carbon polycyclic group in which any two rings share two non-directly bonded carbon atoms, and may contain one or more double bonds. Preferably, it is 6- to 14-membered (i.e., 6- to 14-membered bridged cycloalkyl), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered bridged cycloalkyl). Depending on the number of constituent rings, it can be classified as bicyclic and polycyclic (e.g., tricyclic, tetracyclic, etc.) bridged cycloalkyl, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:

[0196]

[0197] The cycloalkyl ring comprises a cycloalkyl group (including monocyclic, spirocyclic, fused, and bridged rings) fused to an aryl, heteroaryl, or heterocyclic alkyl ring as described above, wherein the ring attached to the parent structure is a cycloalkyl group. Non-limiting examples include... etc.; preferably

[0198] The cycloalkyl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0199] The term "alkoxy" refers to -O-(alkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, and butoxy. Alkoxy groups can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably selected from D atoms, halogens, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclic oxy groups, hydroxyl groups, hydroxyalkyl groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups.

[0200] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic substituent containing 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 3 to 20 membered heterocyclic groups), wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxides or sulfones), but does not include the -OO-, -OS-, or -SS- ring moiety, and the remaining ring atoms are carbon. Preferably, it contains 3 to 14 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14) ring atoms (i.e., 3 to 14-membered heterocyclic groups), wherein 1 to 4 (e.g., 1, 2, 3, and 4) are heteroatoms; more preferably, it contains 3 to 8 ring atoms (e.g., 3, 4, 5, 6, 7, and 8) or 6 to 14 ring atoms (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14), wherein 1 to 3 are heteroatoms (e.g., 1, 2, and 3); even more preferably, it contains 3 to 8 ring atoms (i.e., 3 to 8-membered heterocyclic groups), wherein 1 to 3 (e.g., 1, 2, and 3) are heteroatoms; most preferably, it contains 5 or 6 ring atoms (i.e., 5-membered or 6-membered heterocyclic groups), wherein 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and homopiperazinyl. Polycyclic heterocyclic groups include spiroheterocyclic, fused heterocyclic, and bridged heterocyclic groups.

[0201] The term "spiroheterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group (i.e., a 5- to 20-membered spiroheterocyclic group) in which one or more ring atoms share a single atom (called a spiro atom) between the rings, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, and the sulfur may optionally be oxidized (i.e., forming a sulfoxide or sulfone), and the remaining ring atoms are carbon. It may contain one or more double bonds. Preferably, it is a 6- to 14-membered group (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14-membered group) (i.e., a 6- to 14-membered spiroheterocyclic group), more preferably a 7- to 10-membered group (e.g., 7, 8, 9, or 10-membered group) (i.e., a 7- to 10-membered spiroheterocyclic group). Spiroheterocyclic groups are classified into monospiroheterocyclic groups and polyspiroheterocyclic groups (such as bispiroheterocyclic groups) according to the number of shared spiro atoms between the rings, with monospiroheterocyclic groups and bispiroheterocyclic groups being preferred. More preferably, they are 3 / 4, 3 / 5, 3 / 6, 4 / 4, 4 / 5, 4 / 6, 5 / 3, 5 / 4, 5 / 5, 5 / 6, 5 / 7, 6 / 3, 6 / 4, 6 / 5, 6 / 6, 6 / 7, 7 / 5, or 7 / 6 monospirocyclic heterocyclic groups. Non-limiting examples of spirocyclic groups include:

[0202]

[0203] The term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group (i.e., a 5- to 20-membered fused heterocyclic group) in which each ring in the system shares an adjacent pair of atoms with other rings in the system. One or more rings may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is a 6- to 14-membered group (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14-membered group) (i.e., a 6- to 14-membered fused heterocyclic group), more preferably a 7- to 10-membered group (e.g., 7, 8, 9, or 10-membered group) (i.e., a 7- to 10-membered fused heterocyclic group). Based on the number of constituent rings, fused heterocyclic groups can be classified into bicyclic and multicyclic (e.g., tricyclic, tetracyclic, etc.) fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of fused heterocyclic groups include:

[0204]

[0205] The term "bridged heterocyclic group" refers to a 5- to 20-membered (i.e., 5- to 20-membered bridged heterocyclic group) polycyclic heterocyclic group in which any two rings share two non-directly connected atoms. It may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is 6- to 14-membered (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14-membered) (i.e., 6- to 14-membered bridged heterocyclic groups), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered bridged heterocyclic groups). Depending on the number of constituent rings, it can be classified into bicyclic and polycyclic (e.g., tricyclic, tetracyclic, etc.) bridged heterocyclic groups, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:

[0206]

[0207] The heterocyclic ring comprises a heterocyclic group (including monocyclic, spirocyclic, fused heterocyclic, and bridged heterocyclic rings) fused to an aryl, heteroaryl, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heterocyclic group, and non-limiting examples include:

[0208] wait.

[0209] The heterocyclic group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0210] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic is a ring sharing adjacent carbon atom pairs) group having a conjugated π-electron system (i.e., 6- to 14-membered aryl), preferably 6- to 10-membered (i.e., 6- to 10-membered aryl), such as phenyl and naphthyl. The aryl ring comprises an aryl ring fused to a heteroaryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is an aryl ring, and non-limiting examples include:

[0211]

[0212] The aryl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0213] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 (e.g., 1, 2, 3, and 4) heteroatoms and 5 to 14 ring atoms (i.e., 5 to 14-membered heteroaryl), wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl is preferably 5 to 10-membered (e.g., 5, 6, 7, 8, 9, or 10-membered) (i.e., 5 to 10-membered heteroaryl), more preferably 8 to 10-membered (e.g., 8, 9, or 10-membered), and more preferably 5 or 6-membered (i.e., 5 or 6-membered heteroaryl), such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc. The heteroaryl ring comprises a heteroaryl ring fused to an aryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include:

[0214]

[0215]

[0216] The heteroaryl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0217] The aforementioned cycloalkyl, heterocyclic, aryl, and heteroaryl residues include residues derived from removing one hydrogen atom from a parent ring atom, or residues derived from removing two hydrogen atoms from the same ring atom or two different ring atoms of the parent, namely "divalent cycloalkyl", "divalent heterocyclic", "aryl", and "heteroaryl".

[0218] The term "amino protecting group" is used to protect the amino group by a group that is easily removed, so that the amino group remains unchanged when other parts of the molecule react. Non-limiting examples include (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butoxycarbonyl (Boc), acetyl, benzyl, allyl, and p-methoxybenzyl, etc. These groups may optionally be replaced by 1-3 substituents selected from halogens, alkoxy groups, and nitro groups. Preferably, the amino protecting group is Boc.

[0219] The term "hydroxyl protecting group" refers to a group introduced onto a hydroxyl group that is easily removed, used to block or protect the hydroxyl group so that reactions can occur on other functional groups of the compound. Non-limiting examples include: trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl (TBDPS), methyl, tert-butyl, allyl, benzyl (Bn), methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl, p-nitrobenzoyl, etc. Preferably, the hydroxyl protecting group is MOM or Bn.

[0220] The term “cycloalkyloxy” refers to cycloalkyl-O-, where the cycloalkyl group is as defined above.

[0221] The term “heterocyclic oxy group” refers to the heterocyclic group -O-, where the heterocyclic group is as defined above.

[0222] The term "aryloxy group" refers to aryl-O-, where the aryl group is as defined above.

[0223] The term “heteroaryloxy” refers to heteroaryl-O-, where the heteroaryl group is as defined above.

[0224] The term "alkylthio" refers to alkyl-S-, where the alkyl group is as defined above.

[0225] The term "haloalkyl" refers to an alkyl group that has been substituted with one or more halogens, wherein the alkyl group is as defined above.

[0226] The term "haloalkoxy" refers to an alkoxy group that is substituted by one or more halogens, wherein the alkoxy group is as defined above.

[0227] The term “deuterated alkyl” refers to an alkyl group that is replaced by one or more deuterium atoms, wherein the alkyl group is as defined above.

[0228] The term "hydroxyalkyl" refers to an alkyl group that is replaced by one or more hydroxyl groups, wherein the alkyl group is as defined above.

[0229] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0230] The term "hydroxyl group" refers to -OH.

[0231] The term "thiol" refers to -SH.

[0232] The term "amino" refers to -NH2.

[0233] The term "cyano" refers to -CN.

[0234] The term "nitro" refers to -NO2.

[0235] The term "oxo" or "oxo" refers to "=O".

[0236] The term "carbonyl" refers to C=O.

[0237] The term "carboxyl group" refers to -C(O)OH.

[0238] The term "carboxylic acid ester group" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O)O-, where alkyl and cycloalkyl are as defined above.

[0239] Bn stands for benzyl.

[0240] MOM refers to methyl oxymethyl.

[0241] Boc refers to tert-butyloxycarbonyl.

[0242] TIPS stands for triisopropylsilane.

[0243] The compounds and intermediates disclosed herein may also exist in different tautomer forms, and all such forms are included within the scope of this disclosure. The terms "tautomer" or "tautomer form" refer to structural isomers with different energies that can interconvert via low energy barriers. For example, proton tautomers (also known as proton transfer tautomers) include interconversions via proton transfer, such as keto-enol and imine-enamine, lactam-lactamimide isomerization. Examples of keto-enol equilibrium are between A and B as shown below.

[0244]

[0245] All tautomers are within the scope of this disclosure. The nomenclature of compounds does not exclude any tautomers.

[0246] The compounds disclosed herein can exist in specific stereoisomer forms. The term "stereoisomer" refers to isomers with the same structure but different spatial arrangements of atoms. These include cis and trans (or Z and E) isomers, (-)- and (+)- isomers, (R)- and (S)- enantiomers, diastereomers, (D)- and (L)- isomers, tautomers, blocked isomers, conformational isomers, and mixtures thereof (such as racemic mixtures and mixtures of diastereomers). Substituents in the compounds disclosed herein may contain additional asymmetric atoms. All such stereoisomers and mixtures thereof are included within the scope of this disclosure. Optically active (-)- and (+)- isomers, (R)- and (S)- enantiomers, and (D)- and (L)- isomers can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. This disclosure discloses an isomer of a compound, which can be prepared by asymmetric synthesis or with chiral auxiliaries, or, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), by forming a salt of the diastereomer with a suitable optically active acid or base, followed by diastereomer resolution using conventional methods known in the art to obtain the pure isomer. Furthermore, the separation of enantiomers and diastereomers is typically performed by chromatography.

[0247] In the chemical structure of the compounds described in this disclosure, the bonds... This indicates that the configuration is not specified; that is, if chiral isomers exist in the chemical structure, the bond... It can be or Or simultaneously include and Two configurations. For all carbon-carbon double bonds, even if only one configuration is named, both the Z-type and E-type are included.

[0248] The compounds disclosed herein include all suitable isotopic derivatives thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that may be introduced into the compounds of this disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, […]. 2 H (deuterium, D) 3 H (tritium, T) 11 C 13 C 14 C 15 N、 17 O、 18 O、 32 p、 33 p、 33 S, 34 S, 35 S, 36S, 18 F, 36 Cl、 82 Br、 123 I, 124 I, 125 I, 129 I and 131 Grade I, with deuterium as the preferred grade.

[0249] Compared to undeuterated drugs, deuterated drugs offer advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, regardless of radioactivity, are included within the scope of this disclosure. Each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom, wherein the deuterium substitution can be partial or complete; partial deuterium substitution refers to the replacement of at least one hydrogen atom with at least one deuterium atom.

[0250] When a site is specifically designated as deuterium D, the site should be understood as having a deuterium abundance of at least 1,000 times greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 15% deuterium incorporation). The compounds in the examples having a natural abundance greater than deuterium can be at least 1000 times abundant deuterium (i.e., at least 15% deuterium doping), at least 2000 times abundant deuterium (i.e., at least 30% deuterium doping), at least 3000 times abundant deuterium (i.e., at least 45% deuterium doping), at least 3340 times abundant deuterium (i.e., at least 50.1% deuterium doping), at least 3500 times abundant deuterium (i.e., at least 52.5% deuterium doping), at least 4000 times abundant deuterium (i.e., at least 60% deuterium doping), or at least 4500 times abundant deuterium (i.e., at least 67.5% deuterium doping). The abundance of deuterium is at least 5000 times (i.e., at least 75% deuterium doping), at least 5500 times (i.e., at least 82.5% deuterium doping), at least 6000 times (i.e., at least 90% deuterium doping), at least 6333.3 times (i.e., at least 95% deuterium doping), at least 6466.7 times (i.e., at least 97% deuterium doping), at least 6600 times (i.e., at least 99% deuterium doping), at least 6633.3 times (i.e., at least 99.5% deuterium doping), or higher.

[0251] "Optional" or "optional" means that the event or situation subsequently described may, but is not necessarily, occur; the description includes the possibility or possibility that the event or situation may or may not occur. For example, "optionally halogenated or cyano-substituted C..." 1-6 "Alkyl" means that halogens or cyano groups may or may not be present. This description includes cases where alkyl groups are substituted by halogens or cyano groups and cases where alkyl groups are not substituted by halogens or cyano groups.

[0252] "Substituted" refers to one or more hydrogen atoms in a group, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms, which are independently substituted by the corresponding number of substituents. Those skilled in the art can determine possible or impossible substitutions without much effort (through experimentation or theory). For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).

[0253] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their pharmaceutically acceptable salts or prodrugs, along with other chemical components, such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and its biological activity.

[0254] "Pharmacologically acceptable salt" refers to the salt of the compounds disclosed herein, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals and possess the expected biological activity. They can be prepared separately during the final isolation and purification of the compound, or by reacting a suitable group with a suitable base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include both inorganic and organic acids.

[0255] For the purposes of pharmaceuticals or pharmacologically active agents, the term "therapeutic effective amount" refers to the amount of a drug or agent sufficient to achieve or at least partially achieve the intended effect. The determination of the therapeutic effective amount varies from person to person, depending on the recipient's age and general condition, as well as the specific active substance. The appropriate therapeutic effective amount in a given case can be determined by a person skilled in the art based on routine testing.

[0256] As used herein, the term "pharmaceutically acceptable" means that these compounds, materials, compositions, and / or dosage forms are suitable for contact with patient tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, within reasonable medical judgment, have a reasonable benefit / risk ratio, and are effective for their intended use.

[0257] As used herein, the singular forms of “a,” “an,” and “the” include plural references, and vice versa, unless the context clearly indicates otherwise.

[0258] When the term "about" is applied to parameters such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As those skilled in the art will understand, when a parameter is not critical, figures are usually given for illustrative purposes only, not as limitations.

[0259] The method for synthesizing the compounds disclosed herein

[0260] In order to achieve the purpose of this disclosure, the following technical solution is adopted:

[0261] Option 1

[0262] A method for preparing the compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising:

[0263] A compound of general formula (IA) or a salt thereof undergoes a deprotection reaction under acidic conditions to yield a compound of general formula (I) or a pharmaceutically usable salt thereof; optionally, when R 3 and / or R 6 When the group contains a protecting group, the deprotection reaction may include the removal of R under acidic or basic conditions before, during, or after the deprotection reaction. 3 and / or R 6 The step of adding a protecting group to the group; preferably, the protecting group is a hydroxyl protecting group (MOM);

[0264] Where R is an amino protecting group; preferably Boc;

[0265] G 2 For NH;

[0266] Ring A, Ring B, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in general formula (I).

[0267] Option 2

[0268] This disclosure discloses a method for preparing the compound of formula (I-1) or a pharmaceutically acceptable salt thereof, the method comprising:

[0269] R 0 The protecting group is a hydrogen atom or a hydroxyl group; the hydroxyl protecting group is preferably a MOM.

[0270] When R 0 When the hydrogen atom is present, the compound of general formula (I-1A) or its salt is deamino protecting group R under acidic conditions to obtain the compound of general formula (I-1) or its pharmaceutically usable salt.

[0271] When R 0When the protecting group is a hydroxyl group, compounds of general formula (I-1A) or their salts lose the hydroxyl protecting group R under acidic conditions. 0 With an amino protecting group R, a compound of general formula (I-1) or its pharmaceutically usable salt is obtained;

[0272] in,

[0273] R is an amino protecting group; preferably Boc;

[0274] G 2 For NH;

[0275] Ring A, Ring B, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 , m, n, p, q, r and t are as defined in general formula (I-1).

[0276] Option 3

[0277] A method for preparing the compound of formula (II) or a pharmaceutically acceptable salt thereof, comprising:

[0278]

[0279] A compound of general formula (IIA) or a salt thereof undergoes a deprotection reaction under acidic conditions to yield a compound of general formula (II) or a pharmaceutically usable salt thereof; optionally, when R 3 and / or R 6 When the group contains a protecting group, the deprotection reaction may include the removal of R under acidic or basic conditions before, during, or after the deprotection reaction. 3 and / or R 6 The step of adding a protecting group to the group; preferably, the protecting group is a hydroxyl protecting group (MOM);

[0280] Where R is an amino protecting group; preferably Boc;

[0281] G 2 For NH;

[0282] Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R6 m, n, p, q, r and t are as defined in general formula (II).

[0283] Option 4

[0284] This disclosure includes a method for preparing the compound of formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising:

[0285]

[0286] R 0 The protecting group is a hydrogen atom or a hydroxyl group; the hydroxyl protecting group is preferably a MOM.

[0287] When R 0 When the hydrogen atom is present, the compound of general formula (II-1A) or its salt is deamino protecting group R under acidic conditions to obtain the compound of general formula (II-1) or its pharmaceutically usable salt.

[0288] When R 0 When the protecting group is a hydroxyl group, compounds of general formula (II-1A) or their salts lose the hydroxyl protecting group R under acidic conditions. 0 With an amino protecting group R, a compound of general formula (II-1) or its pharmaceutically usable salt is obtained;

[0289] in,

[0290] R is an amino protecting group; preferably Boc;

[0291] G 2 For NH;

[0292] Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in general formula (II-1).

[0293] The reagents providing acidic conditions in the above synthesis scheme include organic acids and inorganic acids. The organic acids include, but are not limited to, trifluoroacetic acid, formic acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, Me3SiCl, and TMSOTf. The inorganic acids include, but are not limited to, hydrogen chloride, dioxane hydrochloride solution, hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid. Dioxane hydrochloride solution is preferred.

[0294] The reagents providing alkaline conditions in the above synthesis schemes include organic and inorganic bases. The organic bases include, but are not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, diisopropylaminolithium, potassium acetate, sodium tert-butoxide, potassium tert-butoxide, tetrabutylammonium fluoride, tetrahydrofuran solution of tetrabutylammonium fluoride, or 1,8-diazabicycloundec-7-ene. The inorganic bases include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, sodium acetate, potassium acetate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, cesium fluoride, and potassium hydroxide.

[0295] The reactions described above are preferably carried out in a solvent, which may include, but is not limited to, pyridine, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromoethane, and mixtures thereof. Detailed Implementation

[0296] The following embodiments are used to further describe this disclosure, but these embodiments are not intended to limit the scope of this disclosure.

[0297] Example

[0298] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰. -6 The unit (ppm) is given. NMR determination was performed using a Bruker AVANCE-400 NMR spectrometer or a Bruker AVANCE NEO 500M. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).

[0299] MS measurements were performed using an Agilent 1200 / 1290DAD-6110 / 6120 Quadrupole MS liquid chromatography-mass spectrometry system (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS).

[0300] waters ACQuity UPLC-QD / SQD (Manufacturer: waters, MS model: waters ACQuity QdaDetector / waters SQ Detector)

[0301] THERMO Ultimate 3000-Q Exactive (Manufacturer: THERMO, MS Model: THERMO QExactive)

[0302] High-performance liquid chromatography (HPLC) analysis was performed using an Agilent HPLC 1200DAD, an Agilent HPLC 1200VWD, and a Waters HPLC e2695-2489 liquid chromatograph.

[0303] Chiral HPLC analysis was performed using an Agilent 1260DAD high-performance liquid chromatograph.

[0304] High performance liquid chromatography (HPLC) was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP, and Gilson GX-281 preparative chromatographs.

[0305] Chiral preparation was performed using a Shimadzu LC-20AP preparative chromatograph.

[0306] The CombiFlash rapid preparation system uses a CombiFlash Rf200 (TELEDYNE ISCO).

[0307] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a diameter of 0.15 mm to 0.2 mm, and the diameter of the silica gel plates used for thin-layer chromatography separation and purification products is 0.4 mm to 0.5 mm.

[0308] Silica gel column chromatography generally uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.

[0309] Mean inhibition rate of kinases and IC 50 The values ​​were determined using a NovoStar microplate reader (BMG GmbH, Germany).

[0310] The known starting materials disclosed herein can be synthesized using or in accordance with methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, and Darui Chemicals.

[0311] Unless otherwise specified in the examples, all reactions can be carried out under an argon or nitrogen atmosphere.

[0312] Argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen gas balloon with a volume of approximately 1L.

[0313] A hydrogen atmosphere refers to a reaction flask connected to a hydrogen balloon with a volume of approximately 1L.

[0314] The pressurized hydrogenation reaction was performed using a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0315] The hydrogenation reaction is usually carried out under vacuum, filled with hydrogen gas, and repeated 3 times.

[0316] The microwave reaction was performed using a CEM Discover-S 908860 microwave reactor.

[0317] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.

[0318] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20℃~30℃.

[0319] The reaction process in the examples was monitored using thin-layer chromatography (TLC). The developing solvent used in the reaction, the eluent system for column chromatography used to purify the compounds, and the developing solvent system for TLC included: A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system. The volume ratio of the solvent was adjusted according to the polarity of the compounds, and small amounts of basic or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.

[0320] Example 1

[0321] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-6-methyl-5,6,7,8-tetrahydroquinazolin-7-yl)naphthol (a mixture of diastereomers)1

[0322] first step

[0323] 3-(3-(benzyloxy)naphth-1-yl)-4-methylcyclohexane-1-one (a mixture of diastereomers) 1c

[0324] Compounds 2-(3-(benzyloxy)naphth-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxoboronylcyclopentane 1a (1 g, 2.77 mmol), (±)-4-methylcyclo-2-en-1-one 1b (310 mg, 2.81 mmol, Shanghai Shaoyuan), potassium trimethylsilanolate (713 mg, 5.55 mol, Shanghai Shaoyuan), and (1,5-cyclooctadiene) rhodium chloride (I) dimer (100 mg, 202.8 μmol, Shanghai Bide) were dissolved in 10 mL of a mixed solution of 1,4-dioxane and water (V:V = 5:1). The reaction was carried out at 80°C for 14 hours under a nitrogen atmosphere. The reaction solution was cooled to room temperature, diluted with 30 mL of water, and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 1c (800 mg, yield: 83.6%). MS m / z (ESI): 345.2 [M+1].

[0325] Step 2

[0326] 4-(3-(benzyloxy)naphth-1-yl)-5-methyl-2-oxocyclohexane-1-carboxylic acid ethyl ester (a mixture of diastereomers) 1d

[0327] Compound 1c (0.8 g, 2.32 mmol) and diethyl carbonate (2.4 g, 20.31 mmol, Sinopharm) were dissolved in tetrahydrofuran (20 mL), and sodium hydride (279 mg, 6.97 mmol, 60% purity) was added. The mixture was heated to 70 °C and reacted for 2 hours. The reaction solution was cooled to room temperature, and saturated ammonium chloride aqueous solution (20 mL) was added. The mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 1d (420 mg, yield: 43.4%). MS m / z (ESI): 417.2 [M+1].

[0328] Step 3

[0329] 7-(3-(benzyloxy)naphth-1-yl)-6-methyl-5,6,7,8-tetrahydroquinazolin-2,4(1H,3H)-dione (a mixture of diastereomers) 1e

[0330] Compound 1d (420 mg, 1.01 mmol), urea (150 mg, 2.49 mmol), and sodium methoxide (120 mg, 2.22 mmol) were dissolved in methanol (30 mL) and refluxed for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to give the title compound 1e (390 mg, yield: 93.7%). MS m / z (ESI): 413.2 [M+1].

[0331] Step 4

[0332] 7-(3-(benzyloxy)naphth-1-yl)-2,4-dichloro-6-methyl-5,6,7,8-tetrahydroquinazoline (a mixture of diastereomers) 1f

[0333] Compound 1e (390 mg, 945.50 μmol) was dissolved in phosphorus oxychloride (10 mL) and reacted at 100 °C for 6 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give the title compound 1f (220 mg, yield: 51.7%).

[0334] MS m / z(ESI):448.9[M+1].

[0335] Step 5

[0336] (1R,5S)-3-(7-(3-(benzyloxy)naphth-1-yl)-2-chloro-6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (a mixture of diastereomers) 1g

[0337] Compound 1f (100 mg, 222.53 μmol), (1R,5S)-3,8-diazabicyclo[3.2.1]octyl-8-carboxylic acid tert-butyl ester (50 mg, 235.5291 μmol, Jiangsu Aikang) and N,N-diisopropylethylamine (58 mg, 448.76 μmol) were dissolved in N,N-dimethylformamide (5 mL) and reacted at 80 °C for 2 hours. The reaction solution was cooled to room temperature, diluted with 20 mL of water, and extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give 1 g (110 mg, yield: 79%) of the title compound.

[0338] MS m / z(ESI): 624.9 [M+1].

[0339] Step 6

[0340] (1R,5S)-3-(7-(3-(benzyloxy)naphthyl-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (a mixture of diastereomers) 1i

[0341] 1 g (110 mg, 175.9 μmol) of compound was dissolved in 1,4-dioxane (5 mL), and sodium hydride (25 mg, 625.0 μmol, 60% purity) was added. After stirring for 5 minutes, ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (110 mg, 175.94 μmol, Fibromide) was added for 1 hour, and the reaction was carried out at 90 °C for 6 hours. The reaction solution was cooled to room temperature, and saturated ammonium chloride aqueous solution (20 mL) was added. The mixture was extracted with ethyl acetate (20 mL × 3), and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate, filtered to remove the drying agent, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 1i (85 mg, yield: 64.5%).

[0342] MS m / z(ESI): 748.2 [M+1].

[0343] Step 7

[0344] (1R,5S)-3-(2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-(3-hydroxynaphth-1-yl)-6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (a mixture of diastereomers)1j

[0345] Compound 1i (85 mg, 113.6 μmol) was dissolved in 10 mL of methanol, and 50 mg of 10% palladium on carbon catalyst (wet) was added. The mixture was purged with hydrogen three times and stirred for 6 hours. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated to obtain the title compound 1j (65 mg, yield: 86.9%). The product was used directly in the next reaction without purification. MS m / z (ESI): 658.2 [M+1].

[0346] Step 8

[0347] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-6-methyl-5,6,7,8-tetrahydroquinazolin-7-yl)naphthol (a mixture of diastereomers)1

[0348] Compound 1j (65 mg, 98.8 μmol) was dissolved in 4 mL of 4 M dioxane hydrochloride solution, and the mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure and purified by high performance liquid chromatography (Waters-2545, column: SharpSil-T C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 30%-45%, flow rate: 30 mL / min) to obtain title compound 1 (13 mg, yield: 23.5%). MS m / z (ESI): 558.2 [M+1].

[0349] 1 H NMR (500MHz, MeOD): δ8.11-8.09(d,1H),7.69-7.68(d,1H),7.40-7.37(m,1H),7.32-7.29(m,1H),7.04-7.02(m, 2H),5.37-5.35(m,1H),5.24(m,1H),4.27-4.24(m,1H),4.19-4.15(m,1H),4.10-4.05(m,1H),3.74-3.71(d,2H) ,3.63-3.62(m,2H),3.47-3.42(m,1H),3.26-3.18(m,3H),3.17-3.12(m,1H),3.08-2.99(m,2H),2.86(m,1H),2. 75-2.71(m,1H),2.63-2.58(m,1H),2.33-2.18(m,5H),2.15-2.09(m,2H),2.02-1.79(m,3H),0.95-0.93(d,3H).

[0350] Example 2

[0351] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-6-methyl-5,6,7,8-tetrahydroquinazolin-7-yl)-5-fluoronaphthyl-2-phenol (a mixture of diastereomers)2

[0352]

[0353] Example 3

[0354] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydroquinazolin-7-yl)-5-ethylnaphthyl-2-phenol (a mixture of diastereomers)3

[0355]

[0356] Example 4

[0357] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydroquinazolin-7-yl)-5-fluoronaphthyl-2-phenol (a mixture of diastereomers)4

[0358]

[0359] first step

[0360] (±)-3-(8-fluoro-3-(methoxymethoxy)naphth-1-yl)cyclohexane-1-one 4c

[0361] Compound 2-(8-fluoro-3-(methoxymethoxy)naphth-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxoboronylcyclopentane 4a (1 g, 2.77 mmol, prepared by the method disclosed in Example 282 on page 522 of patent application "WO2021 / 041671"), cyclohexyl-2-en-1-one 4b (310 mg, 2.81 mmol, Shanghai Shaoyuan), potassium phosphate (713 mg, 5.55 mol), and (1,5-cyclooctadiene) rhodium chloride (I) dimer (100 mg, 202.8 μmol, Shanghai Bide) were dissolved in 10 mL of a mixed solution of 1,4-dioxane and water (V:V = 5:1). The reaction was carried out at 80°C for 14 hours under a nitrogen atmosphere. The reaction solution was cooled to room temperature, diluted with 30 mL of water, and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 4c (800 mg, yield: 83.6%).

[0362] MS m / z(ESI): 303.2 [M+1].

[0363] Step 2

[0364] (±)-4-(8-fluoro-3-(methoxymethoxy)naphth-1-yl)-2-oxocyclohexane-1-carboxylic acid ethyl ester 4d

[0365] Compound 4c (0.8 g, 2.32 mmol) was dissolved in tetrahydrofuran (10 mL), stirred at -78 °C for 2 minutes, and then a 1 M solution of lithium bis(trimethylsilylamino)thionate in tetrahydrofuran (7 mL) was added. The mixture was stirred at the same temperature for 1 hour. Ethyl cyanoformate (2.4 g, 20.31 mmol) was added, and the mixture was stirred at the same temperature for another 0.5 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 4d (420 mg, yield: 43.4%).

[0366] MS m / z(ESI): 375.2 [M+1].

[0367] Step 3

[0368] (±)-7-(8-fluoro-3-(methoxymethoxy)naphthyl-1-yl)-2-(methylthio)-5,6,7,8-tetrahydroquinazolin-4-phenol 4e

[0369] Compound 4d (120 mg, 320.5 μmol), S-methylisothiourea hemisulfate (270 mg, 969.9 μmol, Shanghai Shaoyuan), and sodium methoxide (105 mg, 1.9 mol) were dissolved in 5 mL of a mixture of ethanol and water (V:V = 5:1). The reaction mixture was reacted at 50 °C for 3 hours. After cooling to room temperature, the reaction solution was diluted with 10 mL of water and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the drying agent, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 4e (30 mg, yield: 23%). MS m / z (ESI): 401.2 [M+1].

[0370] Step 4

[0371] (±)-7-(8-fluoro-3-(methoxymethoxy)naphthyl-1-yl)-2-(methylthio)-5,6,7,8-tetrahydroquinazolin-4-yltrifluoromethanesulfonate 4f

[0372] Compound 4e (100 mg, 250.9 μmol) was dissolved in 5 mL of dichloromethane, and N,N-diisopropylethylamine (100 mg, 773.7 μmol) and trifluoromethanesulfonic anhydride (85 mg, 310.2 μmol) were added. The mixture was reacted at 0 °C for 2 hours. The reaction solution was concentrated under reduced pressure after cooling. The residue was purified by silica gel column chromatography using eluent system B to give the title compound 4f (100 mg, yield: 75%).

[0373] MS m / z(ESI): 533.2 [M+1].

[0374] Step 5

[0375] (1R,5S)-3-(7-(8-fluoro-3-(methoxymethoxy)naphthyl-1-yl)-2-(methylthio)-5,6,7,8-tetrahydroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1] tert-butyl octane-8-carboxylate 4g

[0376] Compound 4f (40 mg, 75.3 μmol), (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (20 mg, 94.2 μmol, Jiangsu Aikang) and N,N-diisopropylethylamine (60 mg, 464.2 μmol) were dissolved in N,N-dimethylformamide (5 mL), and reacted at 0 °C for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give the title compound 4 g (30 mg, yield: 67%).

[0377] MS m / z(ESI): 595.2 [M+1].

[0378] Step 6

[0379] (1R,5S)-3-(7-(8-fluoro-3-(methoxymethoxy)naphth-1-yl)-2-(methylsulfinyl)-5,6,7,8-tetrahydroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 4h

[0380] 4 g (36 mg, 60.5 μmol) of compound was dissolved in ethyl acetate (5 mL), and m-chloroperoxybenzoic acid (12 mg, 69.5 μmol) was added. The mixture was stirred for 14 hours. The reaction solution was quenched with saturated sodium thiosulfate aqueous solution and washed with saturated sodium bicarbonate aqueous solution. The organic phase was concentrated under reduced pressure to obtain crude title compound 4h (36 mg, yield: 97%). The product was used directly in the next reaction without purification.

[0381] MS m / z(ESI): 611.2 [M+1].

[0382] Step 7

[0383] (1R,5S)-3-(7-(8-fluoro-3-(methoxymethoxy)naphth-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (a mixture of diastereomers) 4i

[0384] The crude compound 4h (37 mg, 60.5 μmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol 1h (20 mg, 125.6 μmol, WuXi AppTec) were dissolved in toluene (3 mL). Sodium tert-butoxide (14 mg, 145.6 μmol) was added under ice bath conditions. The mixture was stirred for 30 minutes while maintaining the temperature. The mixture was then quenched with saturated ammonium chloride aqueous solution and extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the drying agent, and concentrated under reduced pressure to obtain the crude title compound 4i (20 mg, yield: 46%). The product was used directly in the next reaction without purification.

[0385] MS m / z(ESI): 706.2 [M+1].

[0386] Step 8

[0387] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydroquinazolin-7-yl)-5-fluoronaphthyl-2-phenol (a mixture of diastereomers)4

[0388] The crude compound 4i (20 mg, 28.3 μmol) was dissolved in 3 mL of 4 M dioxane hydrochloride solution and stirred for 1 hour. The reaction solution was concentrated under reduced pressure and purified by high performance liquid chromatography (Waters-2545, column: SharpSil-T C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 30%-45%, flow rate: 30 mL / min) to obtain title compound 4 (9 mg, yield: 56.5%). MS m / z (ESI): 562.2 [M+1].

[0389] 1H NMR (500MHz, CD3OD): δ7.50-7.49(d,1H),7.35-7.31(m,1H),7.09-7.06(d,2H),7.00-6.96 (q,1H),5.35-5.24(d,2H),4.21-4.04(m,4H),3.72-3.69(m,1H),3.58-3.57(m,2H),3.39-3 .37(m,2H),3.26-3.18(m,3H),3.06-2.98(m,2H),2.88-2.83(m,1H),2.77-2.72(m,1H),2.6 7-2.64(m,1H),2.32-2.18(m,3H),2.15-2.04(m,2H),1.99-1.94(m,2H),1.91-1.79(m,4H).

[0390] Example 5

[0391] 3-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydroquinazolin-7-yl)-5-chloro-4-cyclopropylphenol (a mixture of diastereomers)5

[0392]

[0393] Using the synthetic route in Example 4, the starting compound 4a in the first step was replaced with compound 2-(3-chloro-2-cyclopropyl-5-(methoxymethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxoboronylpentane (prepared by the method disclosed in Example 283 on page 526 of the specification in patent application "WO2021 / 041671") to obtain title compound 5 (100 mg, yield: 30%).

[0394] MS m / z(ESI): 568.2 [M+1].

[0395] 1H NMR (500MHz, CD3OD): δ6.70(d,1H),6.63(d,1H),5.37(s,1H),5.26(s,1H),4.61(s, 2H),4.27(d,1H),4.18(dd,1H),4.09(dd,1H),3.97-3.90(m,1H),3.81-3.70(m,3H), 3.48(d,2H),3.32-3.21(m,3H),3.11-3.03(m,2H),2.99(dd,1H),2.80(d,1H),2.75- 2.62(m,2H),2.32(dd,1H),2.28-2.16(m,3H),2.15-2.09(m,1H),2.07-1.84(m,8H).

[0396] Example 6

[0397] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydroquinazolin-7-yl)-5,6-difluoronaphthyl-2-phenol (a mixture of diastereomers)6

[0398]

[0399] Using the synthetic route in Example 4, the starting compound 4a in the first step was replaced with compound 2-(7,8-difluoro-3-(methoxymethoxy)naphth-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxoboronylpentane (prepared using the method disclosed in Example 246 on page 437 of patent application "WO2021 / 041671") to obtain title compound 6 (100 mg, yield: 30%).

[0400] MS m / z(ESI): 580.2 [M+1].

[0401] 1H NMR (500MHz, CD3OD): δ7.49(ddd,1H),7.33(td,1H),7.12(d,1H),7.04(t,1H),5.40-5 .28(m,1H),4.27-4.12(m,2H),4.08(dt,2H),3.73(d,1H),3.66(s,2H),3.45-3.38(m, 1H),3.25-3.18(m,3H),3.07(d,1H),3.01(td,1H),2.91-2.81(m,1H),2.77(dd,1H),2 .65(d,1H),2.32-2.25(m,1H),2.20(ddt,2H),2.10(d,2H),2.00(dq,3H),1.89(d,5H).

[0402] Example 7

[0403] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydroquinazolin-7-yl)naphthol (a mixture of diastereomers)7

[0404]

[0405] Using the synthetic route in Example 1, the starting material compound 1b in the first step was replaced with compound 4b to obtain title compound 7 (13 mg, yield: 25.6%).

[0406] MS m / z(ESI): 544.2 [M+1].

[0407] 1 H NMR (500MHz, CD3OD): δ8.08-8.06(d,1H),7.69-7.68(d,1H),7.41-7.38(t,1H), 7.35-7.31(t,1H),7.03-7.01(m,2H),5.37-5.25(m,2H),4.21-4.08(m,3H),3.93 (m,1H),3.75-3.61(m,3H),3.47-3.40(m,1H),3.25-3.13(m,3H),3.09-3.03(m,2 H),2.91-2.81(m,2H),2.67-2.63(m,1H),2.30-1.88(m,10H),1.36-1.31(m,2H).

[0408] Biological evaluation

[0409] Test Example 1: Biological Evaluation of ERK Phosphorylation Inhibition Experiment in AGS Cells (HTRF Method)

[0410] I. Purpose of the Test

[0411] This experiment investigated the inhibitory effect of compounds on cellular ERK phosphorylation, based on IC50 values. 50 The size of the compound was evaluated to assess its inhibitory effect on the KRAS target.

[0412] II. Experimental Methods

[0413] AGS cells (Nanjing Kebai, CBP60476) were cultured in RPMI 1640 (Hyclone, SH30809.01) complete medium containing 10% fetal bovine serum. On the first day of the experiment, AGS cells were seeded at a density of 40,000 cells / well in 96-well plates using complete medium, with 190 μL of cell suspension per well, and incubated overnight at 37°C in a 5% CO2 cell culture incubator.

[0414] On the second day, 10 μL of serially diluted test compounds prepared with complete culture medium was added to each well. The final concentration of the compound was determined by nine concentration points, starting from 10 μM and serially diluted five times. A blank control containing 0.5% DMSO was included. The plate was incubated at 37°C in a cell culture incubator with 5% CO2 for 1 hour. After incubation, the 96-well cell culture plate was removed, the culture medium was aspirated, and each well was washed once with 200 μL of PBS (Shanghai Yuanpei Biotechnology Co., Ltd., B320). The PBS was then aspirated, and each well was added with 50 μL of lysis buffer (Cisbio, 64KL1FDF) containing blocking reagent (Cisbio, 64KB1AAC). The plate was then placed on a shaker and oscillated at room temperature for 40 minutes for lysis. After lysis, the lysis buffer was mixed by pipetting, and 16 μL of lysis buffer was transferred to each well into two HTRF 96-well detection plates (Cisbio, 66PL96100). Then, 4 μL of premixed phosphorylated ERK1 / 2 antibody solution (Cisbio, 64AERPEG) or 4 μL of premixed total ERK1 / 2 antibody solution (Cisbio, 64NRKPEG) was added to each plate. The microplates were sealed with sealing film, centrifuged for 1 minute, and incubated overnight at room temperature in the dark.

[0415] On the third day, the fluorescence values ​​of excitation at 337 nm and emission at 665 nm and 620 nm were read using the ENVISION multi-functional microplate reader (PerkinElmer, ENVISION).

[0416] III. Data Analysis

[0417] The IC50 of the compound's inhibitory activity was calculated using Graphpad Prism software based on the compound concentration and the ratio of phosphorylated ERK to total ERK. 50 The values ​​are shown in Table 1 below.

[0418] Table 1. Data on cellular ERK phosphorylation inhibition activity

[0419] Example number <![CDATA[AGS / IC 50 (nM)]]> 1 17.2 4 8.6 5 26.4 6 7.2 7 14.7

[0420] Conclusion: The compound disclosed herein has a good inhibitory effect on ERK phosphorylation in AGS cells.

[0421] Test Example 2: SPR method for detecting the affinity of the disclosed compound for KRAS protein isoform G12D or WT

[0422] Biotinylated Avi-KRAS-WT or Avi-KRAS-G12D was first diluted to 20 μg / mL with 1×HBS-P+ (Cat.#BR1006-71) buffer containing 100 mM MgCl2, and then flowed through channel 2 of the SA (Cat.#BR1005-31) biosensor chip for 420 s to obtain a coupling level of approximately 5000-7000 RU. Small molecule compound samples were then injected sequentially from low to high coupling levels for 120 s, followed by dissociation for 720 s. A single-cycle kinetic mode was used in the experiment. The reaction signal was monitored in real time using a Biacore 8K instrument to obtain binding and dissociation curves. After the experiment, data analysis was performed using Biacore 8K evaluation software, and a 1:1 model was used to fit the data and obtain affinity data.

[0423] Table 2. Affinity data of compounds with KRAS protein subtypes G12D or WT

[0424]

[0425] Conclusion: The disclosed compound has good affinity for KRAS protein subtypes G12D or WT.

[0426] Test Example 3: Biological Evaluation of GP2d Cell 3D Proliferation Inhibition Experiment

[0427] I. Purpose of the Test

[0428] The inhibitory effect of the disclosed compound on the KRAS target was evaluated by testing its 3D proliferation inhibition effect on GP2d cells.

[0429] II. Experimental Methods

[0430] GP2d cells (Nanjing Kebai, CBP60010) were cultured in complete medium, namely DMEM / high glucose medium (Hyclone, SH30243.01) containing 10% fetal bovine serum (Corning, 35-076-CV). On the first day of the experiment, GP2d cells were seeded at a density of 1000 cells / well in 96-well low-absorption plates (Corning, CLS7007-24EA) using complete medium, with 90 μL of cell suspension per well. After centrifugation at 2000 rpm at room temperature for 5 minutes, the cells were incubated overnight at 37°C in a 5% CO2 cell culture incubator.

[0431] On the second day, 10 μL of serially diluted test compound prepared with complete culture medium was added to each well. The final concentration of the compound in GP2d cells was determined by nine 3-fold serial dilutions starting from 1 μM. A blank control containing 0.5% DMSO was included. The plates were incubated at 37°C in a 5% CO2 incubator for 120 hours. On the seventh day, the 96-well cell culture plate was removed, and 50 μL of CellTiter- was added to each well. The 3D reagent (Promega, G9682) was shaken at room temperature for 25 minutes, then mixed by pipetting and aspiration. 50 μL was transferred to a white, opaque 96-well plate (PE, 6005290), and the luminescence signal value was read using a multi-functional microplate reader (PerkinElmer, ENVISION).

[0432] III. Data Analysis

[0433] The IC50 of the compound's inhibitory activity was calculated using Graphpad Prism software. 50 The values ​​are shown in Table 3 below.

[0434] Table 3. Data on cell 3D proliferation inhibition activity

[0435] Example number <![CDATA[GP2d / IC 50 (nM)]]> 6 28.2 7 67.0

[0436] Conclusion: The compound disclosed herein has a good inhibitory effect on the 3D proliferation of GP2d cells.

Claims

1. A compound of general formula (II-1) or a pharmaceutically acceptable salt thereof: in: G 2 For NH; Ring A is phenyl or naphthyl; L is selected from O; R 1 It is a hydrogen atom; R 2 R 2c R 2a R 2b R 4a and R 4b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 alkyl; Each R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and cyclopropyl; Each R 6 They may be the same or different, and each is an independent halogen; R 5 It is a hydrogen atom; m is 1; n is 0; r is 1; p is 0, 1, 2, 3, 4 or 5; q is 0, 1, 2, 3, 4 or 5; and t is 0, 1, 2, 3, 4 or 5; The compound represented by general formula (II-1) is not , , , .

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 2c All are hydrogen atoms.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 4a and R 4b All are hydrogen atoms.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2a and R 2b They may be the same or different, and each is independently a hydrogen atom or a methyl group.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, ethyl groups, and cyclopropyl groups.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 6 They are the same or different, and each is F independently.

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .

8. A compound of general formula (I-1A) or a salt thereof: in: q can be 0, 1, 2, 3, or 4; R 0 It is a hydrogen atom or hydroxyl protecting group; R is an amino protecting group; Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, r and t are as defined in claim 1.

9. The compound or a salt thereof according to claim 8, wherein, R stands for Boc.

10. A compound having the following structure: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , , , , , , , , , , , , , , , , , , , , , , , , and .

11. A method for preparing the compound of general formula (II-1) according to claim 1 or a pharmaceutically acceptable salt thereof, the method comprising: R 0 It is a hydrogen atom or hydroxyl protecting group; When R 0 When the hydrogen atom is present, the compound of general formula (II-1A) or its salt is deamino protecting group R to obtain the compound of general formula (II-1) or its pharmaceutically usable salt. When R 0 When the protecting group is a hydroxyl group, compounds of general formula (II-1A) or their salts lose the hydroxyl protecting group R. 0 With an amino protecting group R, a compound of general formula (II-1) or its pharmaceutically usable salt is obtained; in, R is an amino protecting group; G 2 For NH; Rings A, L, R 1 R 2 R 2c R 2a R 2b R 3 R 4a R 4b R 5 R 6 m, n, p, q, r and t are as defined in claim 1.

12. The method for processing a compound of general formula (II-1) or a pharmaceutically acceptable salt thereof according to claim 11, wherein, The hydroxyl protecting group is MOM.

13. The method for processing a compound of general formula (II-1) or a pharmaceutically acceptable salt thereof according to claim 11, wherein, R stands for Boc.

14. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, and one or more pharmaceutically acceptable carriers, diluents or excipients.

15. Use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of claim 14 in the preparation of a medicament for inhibiting KRAS G12D.

16. Use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of claim 14 in the preparation of a medicament for treating and / or preventing a disease or condition, wherein the disease or condition is cancer.

17. Use of the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of claim 14 in the preparation of a medicament for treating and / or preventing a disease or condition, wherein the disease or condition is selected from brain cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, laryngeal cancer, oral cancer, salivary gland cancer, esophageal cancer, gastric cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, colorectal cancer, small bowel cancer, gastrointestinal stromal tumor, urothelial carcinoma, urethral cancer, bladder cancer, breast cancer, vaginal cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, hemangioma, leukemia, lymphoma, myeloma, skin cancer, lipoma, bone cancer, soft tissue sarcoma, neurofibroma, glioma, neuroblastoma, and glioblastoma.

18. The use according to claim 17, wherein the disease or condition is selected from pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

Citation Information

Patent Citations

  • Substituted quinazoline compounds and methods of use

    WO2017172979A1

  • Tetrahydroquinazoline derivatives useful as anticancer agents

    WO2019155399A1

  • KRAS g12c inhibitors

    WO2020146613A1

  • Hydropyridopyrimidine derivative, preparation method therefor and medical use thereof

    WO2020238791A1

  • Compounds having inhibitory activity against KRAS G12D mutation

    CN115003677A